SiRNA Negative Control
Based on 27 publication(s) in Google Scholar
SiRNA Negative Control is a siRNA of 21 nucleotides, and can be used as a negative control. SiRNA Negative Control has no homology to most known gene sequence. SiRNA Negative Control can be used in human, mouse and rat cells in vitro. SiRNA Negative Control can be used as experimental control benchmark, verification of experimental reliability and standardization reference. SiRNA Negative Control is a common negative control used in most research articles.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.24%
- Masse moléculaire:13323.03
-
Stockage:
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications Citing Use of MedChemExpress (MCE) SiRNA Negative Control
More- Nat Commun. 2026 Jun 8. [Abstract]
- J Control Release. 2025 Sep 8:387:114192. [Abstract]
- Mol Med. 2025 Sep 29;31(1):307. [Abstract]
- Cancer Biol Ther. 2026 Dec 31;27(1):2678636. [Abstract]
- Ann Hepatol. 2025 Jan 3:101776. [Abstract]
- Am J Physiol Heart Circ Physiol. 2026 Feb 1;330(2):H620-H641. [Abstract]
- Mol Cell Biochem. 2025 Sep 10. [Abstract]
- Circ J. 2025 Jul 4. [Abstract]
- Hum Mutat. 2025 May 30:2025:6771390. [Abstract]
- RSC Med Chem. 2026 Jan 12;17(2):1107-1134. [Abstract]
- Appl Biochem Biotechnol. 2025 Nov 20. [Abstract]
- Naunyn Schmiedebergs Arch Pharmacol. 2025 Apr 21. [Abstract]
- J Bioenerg Biomembr. 2026 May 30;58(1):15. [Abstract]
- Int J Hyperthermia. 2025 Dec;42(1):2583160. [Abstract]
- J Biochem Mol Toxicol. 2025 Dec;39(12):e70645. [Abstract]
- J Orthop Surg Res. 2025 Mar 1;20(1):220. [Abstract]
- J Biochem Mol Toxicol. 2025 Mar;39(3):e70167. [Abstract]
- World J Surg Oncol. 2026 May 23. [Abstract]
- Hereditas. 2025 Aug 14;162(1):158. [Abstract]
- Odontology. 2025 Dec 13. [Abstract]
- Arch Dermatol Res. 2025 Feb 15;317(1):418. [Abstract]
- Mutat Res. 2025 Dec 12:832:111926. [Abstract]
- Mutat Res. 2025 Jun 11:831:111911. [Abstract]
- Cytotechnology. 2026 Jun;78(3):112. [Abstract]
- Cytotechnology. 2025 Aug;77(4):138. [Abstract]
- Ann Agric Environ Med. 2026 May 8.
- Preprints. 2025 Sep 18.
-
Flow Cytometry
-
WB
-
Cell Imaging/Staining
-
RT-PCR
-
Cell Proliferation/Viability Assay
Activité biologique
SiRNA Negative Control is a siRNA of 21 nucleotides, and can be used as a negative control. SiRNA Negative Control has no homology to most known gene sequence. SiRNA Negative Control can be used in human, mouse and rat cells in vitro. SiRNA Negative Control can be used as experimental control benchmark, verification of experimental reliability and standardization reference. SiRNA Negative Control is a common negative control used in most research articles.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
Appearance Solid
-
Masse moléculaire 13323.03
-
Color White to off-white
-
SMILES
[RNA, (UUCUCCGAACGUGUCACGUUU), complex with RNA, (ACGUGACACGUUCGGAGAAUU) (1:1)]
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (27)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
2026 Jun 8. PMID: 42259794 -
J Control Release
Hydrodynamic focusing to synthesize lipid-based nanoparticles: Computational and experimental analysis of chip design and formulation parameters. [Abstract]2025 Sep 8:387:114192. PMID: 40930163 -
Mol Med
EPO-modified bone marrow MSCs alleviate asthma inflammation through enhanced mitochondrial activation and transfer by upregulating HO-1. [Abstract]2025 Sep 29;31(1):307. PMID: 41023810
SiRNA Negative Control purchased from MedChemExpress. Usage Cited in: Mol Med. 2025 Sep 29;31(1):307. [Abstract]
SiRNA Negative Control (Si-NC)- or si-Miro1-transfected mGFP-EPO-BM-MSCs (showing a green fluorescence) were co-cultured with mtCC1-2 cells labeled with CellTrace Violet (showing a blue fluorescence). Flow cytometry analyzed the percentage of mtCC1-2 cells labeled with GFP and CellTrace Violet.
SiRNA Negative Control purchased from MedChemExpress. Usage Cited in: Mol Med. 2025 Sep 29;31(1):307. [Abstract]
Immunoblotting of M-sec in SiRNA Negative Control (Si-NC)- or si-M-sec-transfected EPO-BM-MSCs.
SiRNA Negative Control purchased from MedChemExpress. Usage Cited in: Mol Med. 2025 Sep 29;31(1):307. [Abstract]
Fluorescence microscopy and the percentage of TNT-forming cells between SiRNA Negative Control (si-NC)-transfected EPO-BM-MSCs or si-M-sec-transfected EPO-BM-MSCs.
-
Cancer Biol Ther
Diagnostic and prognostic value of lncSPATA8-AS1 in prostate cancer and its regulatory effect on tumor progression. [Abstract]2026 Dec 31;27(1):2678636. PMID: 42187002 -
Ann Hepatol
The promoting effect of the POU3F2/METTL16/PFKM cascade on glycolysis and tumorigenesis of hepatocellular carcinoma. [Abstract]2025 Jan 3:101776. PMID: 39756795
SiRNA Negative Control purchased from MedChemExpress. Usage Cited in: Ann Hepatol. 2025 Jan 3:101776. [Abstract]
Expression of PFKM mRNA transcript in MHCC97 and Huh-7 HCC cells transfected with SiRNA Negative Control (si-NC) or si-METTL16 (the 1:1 ratio mix of si-METTL16#1:si-METTL16#3) by quantitative PCR (n = 3).
SiRNA Negative Control purchased from MedChemExpress. Usage Cited in: Ann Hepatol. 2025 Jan 3:101776. [Abstract]
SiRNA Negative Control (si-NC) (48 h). CCK-8 cell viability assay in transfected MHCC97 and Huh-7 HCC cells.
-
Am J Physiol Heart Circ Physiol
Comprehensive transcriptomics and proteomics analysis of neointima formation in human saphenous vein: implications for bypass graft disease. [Abstract]2026 Feb 1;330(2):H620-H641. PMID: 41569144 -
Mol Cell Biochem
The oncogenic role of NSUN2 in lung adenocarcinoma by stabilizing CCT5 mRNA via a YBX1-dependent m5C modification. [Abstract]2025 Sep 10. PMID: 40928583 -
Circ J
Role and Mechanism of Rho-Associated Coiled-Coil Containing Protein Kinase 1 (ROCK1) in Lipopolysaccharide-Evoked Pneumonia in Mice and Inflammatory Injuries in WI-38 Fibroblasts. [Abstract]2025 Jul 4. PMID: 40619218 -
Hum Mutat
M1 Macrophage is a Novel Potential Trigger for Endothelial Senescence: Role of Exosomal miR-155 Targeting SOCS1 Signal. [Abstract]2025 May 30:2025:6771390. PMID: 40486266 -
RSC Med Chem
Comprehensive multi-omics analysis and experimental validation indicate that VPS35 is a promising biomarker for prognosis, immunotherapy, and chemotherapy in LIHC. [Abstract]2026 Jan 12;17(2):1107-1134. PMID: 41531939 -
Appl Biochem Biotechnol
Exosomal FOSL1 From Cancer-associated Fibroblasts Drives the Progression and Pro-tumorigenic M2 Macrophage Polarization of Hepatocellular Carcinoma By Activating PLAU Transcription. [Abstract]2025 Nov 20. PMID: 41264215 -
Naunyn Schmiedebergs Arch Pharmacol
Doublecortin-like kinase 1, regulated by STIP1 homology and U-box containing protein 1 or Sp1 transcription factor, affects the malignant behaviors and drug sensitivity in adriamycin-resistant breast cancer cells. [Abstract]2025 Apr 21. PMID: 40257489 -
J Bioenerg Biomembr
The FOXO3/ZC3H13/SLC3A2 cascade modulates the osteogenic differentiation and ferroptosis of BMSCs. [Abstract]2026 May 30;58(1):15. PMID: 42217127 -
Int J Hyperthermia
Hyperthermia upregulates exosomal miR-210-3p to target GPD1L activating PI3K/AKT pathway and promoting atrial fibrosis. [Abstract]2025 Dec;42(1):2583160. PMID: 41392556 -
J Biochem Mol Toxicol
Exosomes From Hepatitis B Virus-Infected Hepatocytes Induce Liver Fibrosis Through METTL3-Mediated m6A Modification of P2RX7 mRNA. [Abstract]2025 Dec;39(12):e70645. PMID: 41405154 -
J Orthop Surg Res
A novel mechanism in regulating drug sensitivity, growth, and apoptosis of bortezomib-resistant multiple myeloma cells: the USP4/KLF2/HMGA2 cascade. [Abstract]2025 Mar 1;20(1):220. PMID: 40022160 -
J Biochem Mol Toxicol
METTL3-Mediated m6A Methylation Stabilizes IFI27 to Drive Esophageal Squamous Cell Carcinoma Progression Through an IGF2BP2-Dependent Mechanism. [Abstract]2025 Mar;39(3):e70167. PMID: 39987518 -
World J Surg Oncol
2026 May 23. PMID: 42177572 -
Hereditas
USP8 protects rat-derived H9C2 cardiomyocytes from doxorubicin-triggered ferroptosis and cell death through deubiquitination-mediated stabilization of MDM4. [Abstract]2025 Aug 14;162(1):158. PMID: 40813720 -
Odontology
VNN1, upregulated by FOXA1, suppresses osteogenic differentiation and promotes inflammation in LPS-induced periodontal ligament stem cells. [Abstract]2025 Dec 13. PMID: 41389271 -
Arch Dermatol Res
METTL3-modified exosomes from adipose-derived stem cells enhance the proliferation and migration of dermal fibroblasts by mediating m6A modification of CCNB1 mRNA. [Abstract]2025 Feb 15;317(1):418. PMID: 39954139 -
Mutat Res
SPDEF-mediated BIRC5 transcriptional activation enhances non-small cell lung cancer progression. [Abstract]2025 Dec 12:832:111926. PMID: 41420920 -
Mutat Res
A novel mechanism in driving non-small cell lung cancer progression: The METTL3/FOXA1/PTK2 cascade. [Abstract]2025 Jun 11:831:111911. PMID: 40541037 -
Cytotechnology
GATA3 mediates the cardioprotective effect of hydroxysafflor yellow a against septic cardiomyopathy: insights from integrated machine learning, WGCNA, and experimental validation. [Abstract]2026 Jun;78(3):112. PMID: 42117033 -
Cytotechnology
The oncogenic role of SPOCK1 in lung carcinoma by promoting immune evasion and its related mechanisms. [Abstract]2025 Aug;77(4):138. PMID: 40626151 -
-
Solvant et solubilité
H2O : 100 mg/mL (7.51 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pureté et documentation
-
Fiche technique (241 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2242 KB)
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 0.0751 mL | 0.3753 mL | 0.7506 mL | 1.8764 mL |
| 5 mM | 0.0150 mL | 0.0751 mL | 0.1501 mL | 0.3753 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.